- Home
- DLXY vs CANF Comparison
DLXY vs CANF Comparison
Compare DLXY & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLXY | CANF |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.7M |
| IPO Year | 2024 | 2011 |
Fundamental Metrics
Financial Performance| Metric | DLXY | CANF |
|---|---|---|
| Price | $0.36 | $3.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 35.8K | 20.4K |
| Earning Date | 05-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.17 |
| 52 Week High | $7.00 | $10.40 |
Technical Indicators
Market Signals| Indicator | DLXY | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 51.76 |
| Support Level | $0.35 | $2.87 |
| Resistance Level | $0.47 | $3.59 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.64 | 41.18 |
Price Performance
Historical ComparisonAbout DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company. Through its subsidiary, it is principally engaged in the trading of oil-related products, which are broadly categorized into crude oil and oil-based products, including naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. These products are traded across multiple countries in Southeast Asia, East Asia, and the Middle East, and the Group has established a presence in the oil trading markets in these countries. The majority of the Group's revenue is generated from the trading of crude oil. Geographically, it derives maximum revenue from its business in East Asia.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.